Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Trophea Development
Swedenipoi.gov.ie ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Trophea Development Ab had a discontinued program involving the NANT Colorectal Cancer Vaccine containing nivolumab (ImmunityBio) targeting PD-1 for colorectal cancer. The company also sponsored a Phase 1 clinical trial investigating a topical combination gel containing triiodothyroacetic acid and dehydroepiandrosterone for skin atrophy due to glucocorticoids, but the current status is unknown as of January 2025[1].
- Therapeutic areas
- DermatologyOncology
- Modalities
- VaccineMonoclonal antibody
- Industry
- Biotech
02
Partnerships
ImmunityBio, Inc.
Beyond the preview
Go deeper on Trophea Development.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trophea Development.